Max Chat
Share chart AbbVie
Extended chart
Simple chart
About AbbVie
19 октября 2011 года Abbott Laboratories объявила о своем плане разделения на две публично торгуемые компании. » Новые " лаборатории Abbott будут специализироваться на разнообразных продуктах, включая медицинские приборы, диагностическое оборудование и продукты питания, в то время как AbbVie будет работать как фармацевтический производитель, основанный на исследованиях
Main settings
IPO date
2013-01-02
ISIN
US00287Y1091
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
3.44
Дивиденд ао
3.28
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 5.59 | 2 |
| P/BV | 93.66 | 1 |
| P/E | 73.65 | 1 |
Efficiency
| Title | Value | Grade |
| ROA | 3.17 | 1 |
| ROE | 62.52 | 10 |
| ROIC | 15.29 | 5 |
Dividends
| Title | Value | Grade |
| Dividend yield | 3.33 | 8.33 |
| DSI | 1 | 10 |
| Average dividend growth | 6.92 | 10 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | 4.5 | 1 |
| Debt/Ratio | 0.4968 | 10 |
| Debt/Equity | 39.18 | 0 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 23 | 4 |
| Yield Ebitda, % | 114.53 | 10 |
| Yield EPS, % | -12.58 | 0 |
Dividends
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 185.39 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Week | 185.3 $ | 0 $ | 0 $ | 0.05 % | 0 % | 0 % |
| Month | 187.34 $ | 183.76 $ | 192.42 $ | -1.04 % | 0 % | 0 % |
| Three month | 173.78 $ | 170.16 $ | 198.47 $ | 6.68 % | 0 % | 0 % |
| Half a year | 192.87 $ | 169.2 $ | 216.66 $ | -3.88 % | 0 % | 0 % |
| Year | 194.02 $ | 164.99 $ | 216.66 $ | -4.45 % | 0 % | 0 % |
| 3 years | 143.08 $ | 132.51 $ | 216.66 $ | 29.57 % | 0 % | 0 % |
| 5 years | 108.22 $ | 80.26 $ | 216.66 $ | 71.31 % | 0 % | 0 % |
| 10 years | 61.38 $ | 48.27 $ | 216.66 $ | 202.04 % | 0 % | 0 % |
| Year to date | 191.83 $ | 169.2 $ | 216.66 $ | -3.36 % | 0 % | 0 % |
Main owners
Contained in ETF
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Mr. Richard A. Gonzalez | Executive Chairman | 7.19M | 1954 (71 year) |
| Mr. Robert A. Michael | CEO & Director | 4.62M | 1970 (55 years) |
| Ms. Elizabeth Shea | Senior Vice President of Investor Relations | N/A | |
| Mr. Timothy J. Richmond | Executive VP & Chief Human Resources Officer | 1.12M | 1966 (59 years) |
| Mr. Jeffrey Ryan Stewart | Executive VP & Chief Commercial Officer | 4.32M | 1969 (56 years) |
| Dr. Azita Saleki-Gerhardt Ph.D. | Executive VP & COO | 3.51M | 1963 (62 years) |
| Mr. Scott T. Reents | Executive VP & CFO | 3.13M | 1968 (57 years) |
| Mr. Sanjay Narayan | Senior VP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal | N/A | |
| Mr. Perry C. Siatis | Executive VP, General Counsel & Secretary | N/A | 1975 (50 years) |
| Dr. Roopal Thakkar M.D. | Executive VP of Research and Development & Chief Scientific Officer | 1972 (53 years) |
About company
Address: United States, North Chicago, 1 North Waukegan Road - Open in google maps, Open in yandex maps
Website: http://www.abbvie.com
Website: http://www.abbvie.com
